It's A Start: Experimental HIV Vaccine Regimen Cuts Disease Risk By A Third In Thai Volunteers
This article was originally published in The Pink Sheet Daily
Executive Summary
Six-year U.S. Army/NIH-sponsored study conducted in 16,000-plus Thai adults shows 31.2% decreased risk of infection, but better efficacy is needed.
You may also be interested in...
The P5 Partnership Starts First Phase III HIV Vaccine Study
The P5 public-private-partnership that includes Sanofi and GlaxoSmithKline has started a pivotal Phase II/III study of a two-vaccine approach to HIV infection prevention, that could be the final nail in the coffin for HIV-AIDS if it works or yet another unwelcome victory for the virus if it doesn’t.
Argos HIV Immunotherapy Offers Potential Reprieve From Antiretrovirals
Through automation and economies of scale, Argos believes its personalized HIV immunotherapy can be "cost competitive with current therapies" with a dosing scheme that offers freedom from ART regimens.
Argos HIV Immunotherapy Offers Potential Reprieve From Antiretrovirals
Through automation and economies of scale, Argos believes its personalized HIV immunotherapy can be "cost competitive with current therapies" with a dosing scheme that offers freedom from ART regimens.